Your browser doesn't support javascript.
loading
Natural history of clinical outcomes and hepatic decompensation in metabolic dysfunction-associated steatotic liver disease.
Noureddin, Nabil; Huang, Daniel Q; Bettencourt, Ricki; Siddiqi, Harris; Majzoub, Abdul M; Nayfeh, Tarek; Tamaki, Nobuharu; Izumi, Namiki; Nakajima, Atsushi; Idilman, Ramazan; Gumussoy, Mesut; Oz, Digdem Kuru; Erden, Ayse; Gidener, Tolga; Allen, Alina M; Ajmera, Veeral; Loomba, Rohit.
Affiliation
  • Noureddin N; Department of Medicine, Division of Gastroenterology and Hepatology, MASLD Research Center, University of California at San Diego, La Jolla, California, USA.
  • Huang DQ; Department of Medicine, Division of Gastroenterology and Hepatology, University of California at San Diego, La Jolla, California, USA.
  • Bettencourt R; Department of Medicine, Division of Gastroenterology and Hepatology, MASLD Research Center, University of California at San Diego, La Jolla, California, USA.
  • Siddiqi H; Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
  • Majzoub AM; Division of Gastroenterology and Hepatology, Department of Medicine, National University Health System, Singapore, Singapore.
  • Nayfeh T; Department of Medicine, Division of Gastroenterology and Hepatology, MASLD Research Center, University of California at San Diego, La Jolla, California, USA.
  • Tamaki N; Department of Medicine, Division of Gastroenterology and Hepatology, MASLD Research Center, University of California at San Diego, La Jolla, California, USA.
  • Izumi N; Evidence-Based Practice Center, Mayo Clinic, Rochester, Minnesota, USA.
  • Nakajima A; Evidence-Based Practice Center, Mayo Clinic, Rochester, Minnesota, USA.
  • Idilman R; Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo, Japan.
  • Gumussoy M; Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo, Japan.
  • Oz DK; Department of Gastroenterology and Hepatology, Yokohama City University, Yokohama, Japan.
  • Erden A; Department of Gastroenterology, Ankara University School of Medicine, Ankara, Turkey.
  • Gidener T; Department of Gastroenterology, Ankara University School of Medicine, Ankara, Turkey.
  • Allen AM; Department of Radiology, Ankara University School of Medicine, Ankara, Turkey.
  • Ajmera V; Department of Radiology, Ankara University School of Medicine, Ankara, Turkey.
  • Loomba R; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
Aliment Pharmacol Ther ; 59(12): 1521-1526, 2024 06.
Article in En | MEDLINE | ID: mdl-38571305
ABSTRACT
BACKGROUND &

AIMS:

The natural progression of hepatic decompensation in metabolic dysfunction-associated steatotic liver disease (MASLD) is not well-characterised. We aimed to describe it by conducting a retrospective analysis.

METHODS:

This longitudinal, retrospective analysis of well-characterised MASLD cohorts followed for hepatic decompensation and death. The sequence of liver-related events was evaluated, and the median time between hepatic decompensation episodes and death versus. transplantation was measured.

RESULTS:

Of the 2016 patients identified, 220 (11%) developed at least one episode of hepatic decompensation during a median follow-up of 3.2 years. Ascites was the most common first liver-related event [153 (69.5%)], followed by hepatic encephalopathy (HE) [55 (25%)] and variceal haemorrhage (VH) [30 (13.6%)]. Eighteen out of the 220 (8.1%) patients had more than one liver-related event as their first hepatic decompensation. Among the patients who had the first episode, 87 (39.5%) had a second episode [44 (50.5%) HE, 31 (35.6%) ascites, and 12 (13.7%) VH]. Eighteen out of 220 (8.1%) had a third episode [10 (55.5%) HE, 6 (33.3%) VH, and 2 (11.1%) ascites]. Seventy-three out of 220 (33.1%) died, and 31 (14%) received liver transplantation. The median time from the first episode to the second was 0.7 years and 1.3 years from the second episode to the third. The median survival time from the first episode to death or transplantation was 2.0 years.

CONCLUSION:

The most common first liver-related event in MASLD patients is ascites. The median survival from the first hepatic decompensation to either death or transplantation is 2 years.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Ascites / Hepatic Encephalopathy / Disease Progression / Fatty Liver Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Aliment Pharmacol Ther Journal subject: FARMACOLOGIA / GASTROENTEROLOGIA / TERAPIA POR MEDICAMENTOS Year: 2024 Document type: Article Affiliation country: Estados Unidos

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Ascites / Hepatic Encephalopathy / Disease Progression / Fatty Liver Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Aliment Pharmacol Ther Journal subject: FARMACOLOGIA / GASTROENTEROLOGIA / TERAPIA POR MEDICAMENTOS Year: 2024 Document type: Article Affiliation country: Estados Unidos